title: Oestrogen receptor antagonist and hair regrowth in dogs with hair cycle arrest (alopecia X).
abstract: An oestrogen receptor pathway that regulates the telogen-anagen hair follicle transition in mice has been described. The purpose of this study was to investigate whether fulvestrant, a pure oestrogen receptor antagonist, would cause hair regrowth in Pomeranian dogs with hair cycle arrest (alopecia X). Eleven Pomeranian dogs with hair cycle arrest were randomly assigned to receive two intramuscular injections of either 10 mg kg(-1) fulvestrant (n = 6) or an equal volume of saline (n = 5) 1 month apart. Complete blood count, chemistry panel, and urinalysis were monitored prior to the first injection and monthly for 2 months. Dogs were evaluated each month for degree of hair growth, percentage of body affected, and quality of new hair growth. Three control dogs received fulvestrant after the completion of the study. In addition, one control dog and one treatment dog received two subcutaneous injections of 20 mg kg(-1) fulvestrant 1 month apart. No dogs that received 10 mg kg(-1) fulvestrant had any evidence of hair regrowth. The control dog that received 20 mg kg(-1) fulvestrant had substantial hair regrowth 1 month after the first injection. No adverse effects from the treatment were noted. Fulvestrant does not appear to be a feasible treatment for dogs with hair cycle arrest (alopecia X) when administered intramuscularly at 10 mg kg(-1). A higher dose of fulvestrant requires more investigation but may be cost-prohibitive.
authors.affiliation: Department of Small Animal Clinical Sciences, University of Tennessee, Knoxville, Tennessee, USA. lfrank@utk.edu
authors.forename: Linda A
authors.initials: LA
authors.lastname: Frank
mesh_terms: D000505:Alopecia / Q000188:drug therapy / Q000662:veterinary*; D000818:Animals; D004283:Dog Diseases / Q000188:drug therapy* / Q000473:pathology; D004285:Dogs; D004958:Estradiol / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004965:Estrogen Antagonists / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D000077267:Fulvestrant; D018859:Hair Follicle; D007273:Injections, Intramuscular / Q000662:veterinary; D008297:Male; D012720:Severity of Illness Index; D016896:Treatment Outcome
chemical_list: D004965:Estrogen Antagonists; D000077267:Fulvestrant; D004958:Estradiol